or Try an Advanced Search...

    Technical Analysis for TSHA - Taysha Gene Therapies, Inc.

    Grade Last Price % Change Price Change
    D 3.24 9.46% 0.28
    TSHA closed up 9.46 percent on Friday, May 24, 2024, on 76 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical TSHA trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Overbought Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 9.46%
    Spinning Top Other 9.46%
    NR7 Range Contraction 9.46%
    Narrow Range Bar Range Contraction 9.46%
    Inside Day Range Contraction 9.46%
    Wide Bands Range Expansion 9.46%
    Wide Bands Range Expansion 9.09%
    Older End-of-Day Signals for TSHA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Upper Bollinger Band 4 days ago
    Upper Bollinger Band Resistance 4 days ago
    Up 10% 4 days ago
    Up 1 ATR 4 days ago
    Up 5% 4 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    TSHA Chart by TradingView
    Basic chart:

    Profile

    Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis

    Is TSHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript
    May 15 Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
    May 14 Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
    May 14 Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.01, revenue of $3.41M beats by $0.85M
    May 14 Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
    May 14 Taysha Gene Therapies upgraded at Jefferies on Rett Syndrome asset
    May 13 Taysha Gene Therapies Q1 2024 Earnings Preview
    May 7 Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
    May 2 Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
    May 2 Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
    See more TSHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.89
    52 Week Low 0.5
    Average Volume 2,516,494
    200-Day Moving Average 2.30
    50-Day Moving Average 2.71
    20-Day Moving Average 2.71
    10-Day Moving Average 2.95
    Average True Range 0.25
    RSI (14) 64.54
    ADX 19.08
    +DI 30.24
    -DI 15.73
    Chandelier Exit (Long, 3 ATRs) 2.53
    Chandelier Exit (Short, 3 ATRs) 2.91
    Upper Bollinger Bands 3.31
    Lower Bollinger Band 2.11
    Percent B (%b) 0.94
    BandWidth 44.21
    MACD Line 0.14
    MACD Signal Line 0.08
    MACD Histogram 0.0562
    Fundamentals Value
    Market Cap 605.75 Million
    Num Shares 187 Million
    EPS -2.87
    Price-to-Earnings (P/E) Ratio -1.13
    Price-to-Sales 23.26
    Price-to-Book 5.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.75
    Resistance 3 (R3) 3.70 3.49 3.67
    Resistance 2 (R2) 3.49 3.36 3.51 3.64
    Resistance 1 (R1) 3.36 3.28 3.43 3.41 3.61
    Pivot Point 3.15 3.15 3.18 3.17 3.15
    Support 1 (S1) 3.02 3.02 3.09 3.07 2.87
    Support 2 (S2) 2.81 2.94 2.83 2.84
    Support 3 (S3) 2.68 2.81 2.82
    Support 4 (S4) 2.73